James Fairlamb, MD
Cardiovascular Disease · Columbia, MONPI 1326029745
Payments from drug & device makers
Across 552 payments — averaging $675.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$146K
- Boehringer Ingelheim$71K
- Pfizer$50K
- Amarin Pharma, Inc.$40K
- Lilly USA, LLC$20K
- Sanofi US Services Inc.$12K
- plus $34K from 25 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 162 | $146,112 |
| Boehringer Ingelheim | 69 | $71,321 |
| Pfizer | 53 | $49,861 |
| Amarin Pharma, Inc. | 60 | $39,795 |
| Lilly USA, LLC | 21 | $20,429 |
| Sanofi US Services Inc. | 8 | $12,033 |
| AstraZeneca | 25 | $10,865 |
| Sanofi-aventis U.S. LLC | 5 | $5,471 |
| Medtronic | 4 | $5,324 |
| Novartis | 8 | $3,446 |
| Boston Scientific | 46 | $2,999 |
| Biotronik Inc. | 23 | $1,975 |
| Regeneron Healthcare Solutions, Inc. | 2 | $992 |
| E.r. Squibb & Sons, L.L.C. | 17 | $340 |
| Johnson & Johnson | 10 | $319 |
| Bayer | 4 | $255 |
| Cvrx, Inc. | 3 | $229 |
| Novo Nordisk | 7 | $221 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $205 |
| Alnylam Pharmaceuticals Inc. | 2 | $189 |
| Impulse Dynamics (USA) Inc. | 2 | $170 |
| Scpharmaceuticals Inc. | 1 | $108 |
| Edwards Lifesciences | 2 | $90 |
| Actelion Pharmaceuticals US, Inc. | 1 | $78 |
| Abbott | 4 | $73 |
| Sanofi | 3 | $58 |
| Merck | 2 | $51 |
| Abiomed | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Shockwave Medical, Inc | 1 | $13 |
How this compares
$373,074 in reported general payments places this provider in the 95th percentile of 391 cardiovascular disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Columbia
- Brian BostickColumbia$147K
- Patrice DelafontaineColumbia$138K
- Sudarshan BallaColumbia$101K
- James ElliottColumbia$83K
- Tillmann CyrusColumbia$47K
- Cristina DanilaColumbia$32K
- Mikhail KosiborodKansas City$27.8M
- Mohammad TahirSaint Louis$2.7M
- John SpertusKansas City$2.3M
- Joshua MitchellSaint Louis$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.